SCHEMBL1633017

SCHEMBL1633017

NS(=O)(=O)c1ccc(Nc2ncc3ccc(-c4ccnc(N5CCOCC5)c4)cc3n2)cc1

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMG1 Q96Q15 5/20 0.72
JAK2 O60674 3/20 0.59
CDK1 P06493 2/20 0.59
CDK2 P24941 2/20 0.59
MTOR P42345 2/20 0.59
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA9 Q16790 3/20 0.53
FLT3 P36888 1/20 0.52
MAPK10 P53779 6/20 0.51
LRRK2 Q5S007 1/20 0.51
JAK3 P52333 1/20 0.49
JUN P05412 2/20 0.48
MAPK8 P45983 2/20 0.48
MAPK9 P45984 1/20 0.48
MAP4K1 Q92918 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631045 0.92 SMG1 (0.59) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1632820 0.90 SMG1 (0.58) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1633026 0.89 SMG1 (0.59) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1631108 0.84 SMG1 (0.70) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1860937 0.82 SMG1 (0.59) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1631926 0.81 MAP4K1 (0.47) SMG1JAK2CDK1CDK2MTOR
SCHEMBL1633843 0.81 MAPK10 (0.54) SMG1JAK2CDK1CDK2MTOR
SCHEMBL13498325 0.80 IKBKB (0.54) JAK2CDK1CDK2CA12CA1
SCHEMBL1633521 0.80 BRAF (0.54) CDK1CDK2MAPK10MAPK8
SCHEMBL13648583 0.79 JAK2 (0.75) SMG1JAK2CDK1CDK2MTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed